Scientists at Georgia State University have achieved a significant breakthrough in the development of a novel oral antiviral agent, demonstrating its remarkable capacity to arrest the spread of a measles-like virus in a preclinical setting. The experimental compound, designated GHP-88310, proved effective in preventing transmission between ferrets through both direct physical proximity and airborne particles, showcasing a dual-action capability that could fundamentally alter outbreak containment strategies. Furthermore, the treatment exhibited a reduction in observable symptoms when administered either prophylactically, just before or after exposure, or therapeutically to already infected subjects.
This groundbreaking research, detailed in the prestigious journal Nature Microbiology, originates from the dedicated efforts of the Center for Translational Antiviral Research (CTAR). The team’s investigation centered on the canine distemper virus (CDV), a pathogen known to induce a disease in ferrets that mirrors many key clinical and pathological features of human measles. This animal model is widely recognized as a highly relevant surrogate for studying measles pathogenesis and antiviral efficacy due to the striking similarities in how the viruses interact with their respective hosts and spread.
The drug candidate, GHP-88310, functions as a broad-spectrum inhibitor targeting the viral polymerase, a critical enzyme indispensable for viral replication. By disrupting this fundamental process, the compound effectively cripples the virus’s ability to proliferate and establish infection. The researchers meticulously evaluated the efficacy of GHP-88310 under conditions designed to simulate real-world transmission scenarios. Their experimental design specifically assessed whether the drug, when administered preemptively, could interrupt the transmission chains initiated by infected individuals.
The study’s findings revealed that prophylactic administration of GHP-88310 entirely thwarted transmission via airborne routes, a feat previously considered exceptionally challenging for antiviral agents. This capability is particularly significant given that airborne transmission is a primary driver of measles outbreaks, allowing the virus to spread rapidly through shared indoor environments. The drug’s ability to block both direct contact and airborne dissemination underscores its potential as a potent tool for preventing localized outbreaks from escalating into widespread epidemics.
Moreover, the research team observed that GHP-88310 also exerted a therapeutic effect when administered to infected ferrets. In these cases, the treatment demonstrably shortened the period during which the animals remained infectious, thereby reducing their capacity to transmit the virus to others. This dual therapeutic and prophylactic efficacy suggests that GHP-88310 could serve as a valuable adjunct to existing public health interventions, such as traditional ring vaccination strategies, offering a new layer of defense against the resurgence of measles.
Dr. Richard Plemper, a Regents’ Professor and Director of CTAR, emphasized the critical importance of swift intervention in controlling measles outbreaks. He stated, "The rapid containment of measles outbreaks is paramount to regaining control over this persistent viral threat. Our recent development of the drug candidate GHP-88310 has now been validated by this study, which conclusively demonstrates its suitability for augmenting conventional ring vaccination efforts against measles." The urgency for such advancements is underscored by the concerning epidemiological landscape.
The North American continent has recently witnessed a disturbing resurgence of measles, with the United States reporting thousands of infections, hundreds of hospitalizations, and multiple fatalities since 2025. Similar severe outbreaks, accompanied by significant mortality, have also been documented in Canada and Mexico. These alarming trends have ignited widespread concern regarding the continent’s ability to maintain its hard-won measles elimination status, highlighting the pressing need for innovative countermeasures.
Carolin Lieber, the study’s first author and a senior postdoctoral fellow in the Plemper lab, expressed considerable enthusiasm regarding the compound’s performance. "We were exceptionally encouraged to observe that oral administration of GHP-88310 completely prevented airborne transmission in our ferret model of measles," she commented. "This outcome is unprecedented for a viral polymerase inhibitor and serves as a testament to the remarkable antiviral potency of this drug."
To accurately replicate the dynamics of viral spread in human populations, the researchers meticulously designed their experimental setup to mimic common living and educational environments. They established a controlled system wherein infected and uninfected ferrets were either placed in direct physical contact or shared the same enclosed airspace without direct physical interaction, thereby simulating different modes of transmission.
Dr. Plemper elaborated on the study’s design, stating, "We engineered the study to recapitulate viral transmission scenarios that occur between individuals with close physical contact, such as within a household setting, and between individuals with more distant social interactions, for example, in classrooms or other indoor communal spaces where people are in proximity but without direct physical exchange." He further noted the potential broader societal benefits: "Beyond its prophylactic advantage, GHP-88310, when used therapeutically, reduced the duration of illness in our model. If this proves applicable to human patients, it could significantly mitigate the considerable social and economic disruptions associated with prolonged patient quarantine and further enhance outbreak management capabilities."
With the promising preclinical results in hand, the researchers are now actively preparing GHP-88310 for formal clinical trials in human subjects. This critical next step aims to validate the safety and efficacy of the compound in a clinical setting, paving the way for its potential deployment as a vital new weapon in the global fight against measles. The successful transition from preclinical research to human trials represents a crucial milestone in the long and complex journey of drug development.
The collaborative effort that underpinned this research involved several key contributors from Georgia State University’s Institute for Biomedical Sciences, including Josef Wolf, Claire Ruckel, and Lauren Harrison, all affiliated with the Center for Translational Antiviral Research. Funding for this significant scientific endeavor was provided by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), underscoring the national commitment to addressing infectious disease threats.
About the Author
